- Home
- PBYI vs OPRX Comparison
PBYI vs OPRX Comparison
Compare PBYI & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | OPRX |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 222.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | OPRX |
|---|---|---|
| Price | $7.04 | $10.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 411.3K | 262.6K |
| Earning Date | 02-26-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | 0.00 |
| Revenue | ★ $211,995,000.00 | $109,506,000.00 |
| Revenue This Year | N/A | $19.77 |
| Revenue Next Year | N/A | $11.33 |
| P/E Ratio | ★ $9.16 | $5,986.94 |
| Revenue Growth | N/A | ★ 24.18 |
| 52 Week Low | $2.58 | $3.99 |
| 52 Week High | $7.21 | $22.25 |
Technical Indicators
Market Signals| Indicator | PBYI | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.59 | 29.06 |
| Support Level | $6.27 | $11.45 |
| Resistance Level | $6.64 | $11.24 |
| Average True Range (ATR) | 0.32 | 0.73 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 89.15 | 16.21 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.